Kai Larson joined Signpath Pharma in May of 2015 as VP, Business Development, General Counsel, and COO. He has served as Signpath’s President since May, 2017. Prior to joining Signpath, he served as the Vice President and Associate General Counsel of The Sun Products Corporation in Salt Lake City, Utah, where he managed legal affairs for a major consumer products company, focusing on commercial contracts, regulatory compliance, government interactions, and patents.
From 2008-2009, he was an attorney in the Life Sciences Group at Axiom Legal, where he counseled pharmaceutical companies regarding clinical trials, pharmaceutical marketing compliance, and intellectual property.
Prior to working at Axiom, Mr. Larson served as the Vice President, General Counsel, and Secretary of Tapestry Pharmaceuticals (NasdaqCM: TPPH), a biotech company in Boulder, Colorado which was focused on oncology and genetic diseases. He joined Tapestry Pharmaceuticals in 1994 as the Director of Legal Affairs under its former name, Napro Biotherapeutics, and helped oversee its IPO in 1996.
Mr. Larson began his career in 1992 as an associate attorney in the Intellectual Property Practice Group at Kirkland & Ellis in New York. He earned his Juris Doctor from Columbia University School of Law and his Bachelor of Arts in Chinese from Brigham Young University.
Peter P. Sordillo, M.D., M.A., M.Phil, Ph.D., M.S.
VICE PRESIDENT, CHIEF SCIENCE OFFICER
Dr. Sordillo joined Signpath as Chief Science and Medical Officer in June of 2017. Prior to that time, Dr. Sordillo had served as Signpath’s Director, Clinical Affairs and a member of Signpath’s Scientific Advisory Board.
Dr. Sordillo is an attending physician, Medical Oncology and Hematology, Lenox Hill Hospital, North Shore-Long Island Jewish Health System. He is also a research consultant at the Institute for Ultrafast Spectroscopy and Lasers, Physics Dept., City University of New York. Dr. Sordillo had previously served for 13 years as a fellow and an attending physician at the Memorial Sloan-Kettering Cancer Center in New York.
His academic appointments have included Instructor in Biophysics at the Cornell University Graduate School of Medical Sciences; Assistant Professor of Medicine, Cornell University Medical College; Associate Professor of Medicine, Mount Sinai School of Medicine; and Associate Professor of Medicine at the New York University School of Medicine.
Dr. Sordillo received his A.B from Columbia College in New York; an M.D. from New York Medical College; an M.S. in Physics from New York University; and two additional Master’s degrees and a Ph.D. (Quantum physics and causality) from Columbia University.
Dr. Sordillo is board-certified in both internal medicine and medical oncology, and is the author of more than 150 journal articles, conference proceedings and book chapters.
Stephen Spencer, S.B.S.
CHIEF FINANCIAL OFFICER
Stephen Spencer joined Signpath Pharma in December 2017 as the CFO. Prior to joining Signpath he was the acting CFO for Sack Lunch Productions, a promoter of large outdoor events held throughout the United States and franchised internationally. While at Sack Lunch he supervised PCAOB audits, prepared public company filings with the SEC and prepared a Reg A filing for money raise.
Previously he was a partner with an international venture capital firm, responsible for banking relations, administration and investor relations. He has served as a consultant and advisor to many public and private companies.
He graduated from the University of Utah with a BA degree in accounting and started his career with Price Waterhouse in Los Angeles, CA and Salt Lake City, UT.
Scientific Advisory Board and Collaborators
Consultant and Collaborator, Principal at AD CardioCinetique Inc.
Annie Bouchard completed her undergraduate training in microbiology at the University of Sherbrooke. She was granted her Masters’ degree in Physiology and Endocrinology at the Faculty of Medicine in Sherbrooke, before holding various positions as Scientist in pharmaceutical companies. She joined IPS Therapeutique Inc. in 2001, and is responsible for creating the cardiac cell lines used for regulatory cardiotoxicity testing over the past 15 years. As a study director and senior scientist, she has directed over 100 FDA-mandated, GLPcompliant studies in cardiovascular safety for new drug applications. She has also co-authored several articles on cardiac toxicity and participated in the development of innovative animal models to quantify cardiac adverse events.
Consultant and Collaborator, Principal at AD CardioCinetique Inc.
Dany Salvail completed his undergraduate training in Biochemistry at Bishop’s University, in Canada, before being granted a Ph.D in Thoracic Physiology & Biophysics at the University of Sherbrooke. While pursuing post-graduate training in cardiology in Massachusetts and in Canada, he co-founded IPS Therapeutique Inc., a CRO specializing in preclinical cardiovascular efficacy and safety assessment, in which he still holds a management role. As Director of Pharmacology, he has assembled and implemented cardiac safety testing strategies for over 3000 drug candidates over the last 18 years. The experience gained in testing and co-filing regulatory applications for dozens of classes of compounds and the central role he played in the development of highly successful drugs led to international recognition, presentations given in North America, Europe, Asia, and subsequent work acting as a consultant in preclinical cardiology.
Member of Signpath’s Scientific Advisory Board.
Dr. Sanguinetti is a pioneer in the field of QT prolongation and cardiac arrhythmias.
He is a Professor in the Division of Cardiology at the University of Utah. His research interests include cellular cardiac electrophysiology, ion channel biophysics and pharmacology, and the molecular basis of inherited arrhythmia. Sanguinetti uses biophysical and molecular biological techniques to study the properties of cardiac ion channels.
Twenty years ago he determined that mammalian cardiomyocytes expressed two distinct delayed rectifier K+ currents (IKr, IKs) that could be separated based on their differential sensitivity to class III antiarrhythmic agent. This finding provided an understanding of the cellular mechanisms of a new class of highly specific antiarrhythmic agents and somewhat paradoxically, the later understanding that block of IKr is the major cause of drug-induced QT prolongation and associated risk for malignant arrhythmia. Later, in collaboration with Dr. Mark Keating, he described the physiological consequences of mutations in ion channel genes that cause long QT syndrome, an inherited disorder of ventricular repolarization that can cause sudden death. Sanguinetti discovered that hERG proteins coassemble to form the IKr channel, that KVLQT1 a-subunits and KCNE1 ß-subunits coassemble to form the IKs channel.
Other significant past discoveries include the mechanisms of hERG channel inactivation, a description of the first IKs activator, molecular determinants of drug binding to hERG, KCNQ1 and Kv1.5 channels, and the molecular mechanisms of CaV1.2 channel dysfunction in Timothy syndrome. Sanguinetti received his Ph.D. in Pharmacology from the University of California, Davis. He received postdoctoral training in biophysics from the University of Rochester.
Sanguinetti has served on the editorial boards of Circulation Research, Heart Rhythm, Biophysical Journal, Journal of Cardiovascular Pharmacology, Journal of Cardiovascular Electrophysiology, Journal of Clinical Investigation and Journal of Pharmacology and Experimental Therapeutics.
He is currently a reviewing editor of the Journal of Physiology and serves on the editorial boards of the Journal of General Physiology and Cellular Physiology and Biochemistry. He is a member of the Biophysical Society, the Physiological Society London, and the American Society of Pharmacology and Experimental Therapeutics. He is co-editor of the book “Heart Rate and Rhythm: Molecular Basis, Pharmacological Modulation and Clinical Implications” (Springer Verlag).
Member of Signpath’s Scientific Advisory Board.
Dr. James McChesney, PhD has over 45 years of research and development experience in natural products. He is the founder and Principal of Ironstone Separations, Inc in Oxford, MS and ChromaDex’s Chief Scientific Officer of Natural Products.
He received a B.S. in Chemical Technology from Iowa State University; a M.A. in Botany and a Doctorate in Organic Chemistry, both from Indiana University, with an emphasis on Natural Products. He had a distinguished teaching career as professor of Botany and Medicinal Chemistry at the University of Kansas, and then as professor of Pharmacognosy at the University of Mississippi. He also served as an advisor to the World Health Organization on Traditional Medicines and anti-malarial drug development, and to UNESCO in Natural Products Chemistry. In 1985, he taught natural products chemistry in Brazil as a Fulbright Fellow. From 1978 to 1986, he chaired the Department of Pharmacognosy at Ole Miss.
From 1986 to 1995 he was Director of the Research Institute of Pharmaceutical Sciences at the University of Mississippi where he established the National Center for Natural Products Research, a state-of-the-art 115,00 square-feet R&D facility. In 1986-87 he was President of the American Society of Pharmacognosy, the premier organization of natural products researchers in the world. In 1993 Dr. McChesney was named F.A.P. Barnard Distinguished Professor of Pharmaceutical Sciences at the University of Mississippi. In 1995 he was elected a Fellow of the American Association for the Advancement of Science for his contributions to the development of Artemisinin-based anti-malarials.
He retired from academia in 1996 to take a position as Vice President of Research and Development at NaPro Biotherapeutics, Inc., a natural product pharmaceutical company.
As a recognized expert in medicinal plant development, he frequently lectures and has authored over 40 patents and nearly 200 peer-reviewed publications.
BOARD OF DIRECTORS
Dr. Arthur P. Bollon has served as a director of the Company since May 28, 2008. Dr. Bollon has more than 25 years of experience in biotechnology as a scientist, executive and entrepreneur. Since 2011, Dr. Bollon has been Chairman and CEO of Vitruvian BioMedical, Inc., which is developing an Alzheimer Disease Vaccine and diagnostic technologies. From October 2003, until August 2010, he was the Chairman, President and Chief Executive Officer to HemoBioTech, Inc. which is developing HemoTech, a potential substitute for human blood.
He is a founder and had served as Chairman and Chief Executive Officer of Wadley Biosciences Inc./LPL, a joint venture between Wadley Cancer Center and Phillips Petroleum which focused on cancer and immune disease therapeutics from 1987 to 1991. From 1992 to 2000, he was a founder, Chairman and Chief Executive Officer of Cytoclonal Pharmaceutics Inc. which focused on cancer and infectious disease therapeutics. While at Cytoclonal, he completed an initial public offering. In addition, he has completed research contracts with multiple universities including UCLA, Montana State University, University of California at San Diego, Texas Tech University and University of British Columbia and licensing agreements with Brisol Meyers-Squibb, Phillips Petroleum, Merck & Co. and Nuron Biotech.
Jack Levine was first appointed to the Board of Directors of the Company on July 12, 2010, and currently serves as Chairman of the Audit Committee.
Mr. Levine, a Certified Public Accountant, has been advising private companies for over 30 years. As of November 2011, he was elected Chairman of the Audit Committee of Provista Diagnostics, Inc., a cancer detection and diagnostics company focused on women’s cancer. The company has established partnerships that allow access to some of the most innovative biomarkers in the molecular oncology market. From 1999 to 2007 he served as an Independent Board Member to Pharmanet, Inc. where from 2006-2007, he served as Chairman of the Board; in 2005, was a member of the Nominating Committee, Lead Director in 2004; a member of the Compensation Committee in 2003, a Chairman of the Audit Committee in 1999. Pharmanet is a global drug development services company providing a comprehensive range of services to pharmaceutical biotechnology, generic drug and medical device companies that was traded on Nasdaq and has since been acquired.
From 2004-2008, Mr. Levine served as Chairman of the Audit Committee of Grant Life Sciences (OTCBB), an R&D company focused on early detection of cervical cancer and also providing medical diagnostic kits. From 2000-2006, Mr. Levine was Chairman either of the Audit Committee, Executive Committee or ALCO Committee of Beach Bank, Miami Beach, Florida. He also served as Chairman of the Audit Committees of Prairie Fund (2000-2006) and Bankers Savings Bank (1996-1998).
From 2004-2006, Mr. Levine was a member of the Audit Committee of Miami Dade County School Board, the nation’s third largest school system with an annual budget exceeding $5 Billion. Mr. Levine currently sits on the Board of Biscayne Pharmaceuticals, Inc. Biscayne is a biopharmaceutical company discovering and developing novel therapies based on growth hormone-releasing hormone (GHRH) analogs. Mr. Levine has been a Board Member since January 2013.
Mr. Levine has been a licensed CPA in Florida since 1983 and in New York since 2009. He has been a Committee member of the State of Florida – Florida Bar since 1993 and a Board Member of the Southeast Region of the American Friends of Bar-Ilan University since 2002.
Beth Hecht was first appointed to the SignPath Board of Directors in March of 2017. Ms. Hecht has over 25 years as an attorney, executive and corporate director in the pharmaceutical and biotechnology industries.
Since October 2012 she has served as Managing Director & Chief Legal and Administrative Officer of Auven Therapeutics, a global private equity firm with offices in Ft. Lauderdale, FL, Bermuda, St. Thomas USVI and Switzerland that acquires and invests in proprietary pharmaceutical and biotech product candidates and technologies that address unmet medical needs. At Auven, she is a member of the Executive Team and Investment Committee and responsible for all legal, regulatory, compliance, human resource and administrative teams. Since September 2015, Ms. Hecht has been a member of the Board of Directors of Neos Therapeutics, Inc. (NASDAQ: NEOS) and serves on the Nominating and Governance Committee.
From 2012 to 2013, Ms. Hecht also served as Corporate Secretary and Chief Legal Advisor to Durata Therapeutics, a Chicago, IL based, NASDAQ traded pharmaceutical company that was acquired by Actavis PLC in late 2013. From 2009 through September 2012, Ms. Hecht served as Senior Vice President, General Counsel & Secretary for the Sun Products Corporation, a 2B consumer products company based in Wilton, CT. At Sun, she was the chief legal and compliance officer with responsibility for legal matters, regulatory and governmental affairs, licensing and external partnerships and compliance. She served as a member of the Sun Executive Leadership Team and as the Corporate Secretary and Advisor to the Board of Directors
During 2008 and 2009, she was a Senior Advisor for Life Sciences & Consumer Products for Axiom, a business and legal consulting firm with offices in New York, London, San Francisco, Chicago and Washington D.C. She was served as a strategic consultant for the life science and consumer product divisions of Axiom. From 2001 through 2007, Ms. Hecht was Executive Vice President, General Counsel and Secretary of MedPointe Inc.(formerly known as Carter Wallace Inc.), a specialty pharmaceutical company that was acquired by Meda AB.
Prior to joining MedPointe, Ms. Hecht was Senior Vice President, General Counsel and Secretary of Warner Chilcott PLC, a NASDAQ-traded multinational pharmaceutical company. Before Warner Chilcott, she was Vice President, General Counsel and Secretary of ChiRex, Inc., a NASDAQ-traded international specialty pharmaceutical ingredient and chemical manufacturer, and as Corporate Counsel and Secretary, founded and ran the legal department of Alpharma, Inc., an NYSE multinational pharmaceutical company.
Ms. Hecht began her legal career as an attorney at the New York offices of the national law firms Willkie, Farr & Gallagher and Kirkland & Ellis where she specialized in corporate transactions and intellectual property law. Ms. Hecht holds a B.A. degree (summa cum laude) from Amherst College and a J.D. degree (cum laude) from Harvard Law School.
Robert Seguso was first appointed to the SignPath Board of Directors in March of 2017.
Mr. Seguso is an early investor in SignPath and has been a public relations consultant since 2016. He has been instrumental in helping the Company raise its public profile and gain access to key individuals in various capital markets.
Mr. Seguso began his public career as a professional tennis player since 1983. He has been ranked #1 on the ATP tour in Doubles and #22 in singles. He holds 36 world doubles titles, including: 2 Wimbledon titles (1987-1988), US Open Title (1985) and the French Open (1987.) He was an Olympic Gold Medalist in 1988 and a US Davis Cup Team Member (1985-1991)
Since retiring from professional tennis, Mr. Seguso has been a commercial and residential real estate developer, with developments including apartment complexes, sports complexes, retail commercial properties, and single family homes.
Mr. Seguso has served as an advisor and public relations consultant to various biotech, investment, and public relations firms.